AstraZeneca Wins First Targeted U.S. Approval for PTEN-Deficient Metastatic Prostate Cancer
TipRanks
Last updated: June 15, 2026
AstraZeneca has received U.S. approval for its prostate cancer drug Truqap, marking a significant advancement in biomarker-directed therapies. This approval expands the drug's application beyond breast cancer and targets a specific genetic deficiency in prostate cancer patients.
- AstraZeneca's Truqap (capivasertib), in combination with abiraterone and prednisone, is now approved in the U.S. as the first targeted therapy for PTEN-deficient metastatic prostate cancer. This decision is supported by the Phase III CAPItello-281 trial, which demonstrated a 19% reduced risk of disease progression or death and a 7.5-month increase in median progression-free survival. The approval signifies the growing importance of biomarker-directed treatments in prostate cancer, with roughly one in four metastatic cases being PTEN-deficient. Accompanying this, a PTEN diagnostic has been cleared, and an EU filing is under review, bolstering AstraZeneca's oncology portfolio.
- Analyst ratings for AstraZeneca (GB:AZN) stock are currently a "Buy" with a price target of £180.00. TipRanks' AI Analyst, Spark, has rated AZN as "Outperform," citing strong fundamentals and positive earnings updates, partly offset by technical momentum and valuation concerns. AstraZeneca is a global biopharmaceutical company focused on oncology, rare diseases, and biopharmaceuticals, with products sold in over 125 countries.
